Raj Singh, Robert Sierra, Casey Leimbach, Sidharth Iyer, Eric J Lehrer, Haley Perlow, Rituraj Upadhyay, Sung Jun Ma, Austin Sim, Emile Gogineni, Sujith Baliga, Daniel M Trifiletti, Joshua D Palmer, David J Konieczkowski, Jeremy Brownstein, Nicholas G Zaorzky
{"title":"立体定向消融放疗治疗原发性肺转移性肉瘤：安全性和有效性的系统回顾和荟萃分析。","authors":"Raj Singh, Robert Sierra, Casey Leimbach, Sidharth Iyer, Eric J Lehrer, Haley Perlow, Rituraj Upadhyay, Sung Jun Ma, Austin Sim, Emile Gogineni, Sujith Baliga, Daniel M Trifiletti, Joshua D Palmer, David J Konieczkowski, Jeremy Brownstein, Nicholas G Zaorzky","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers.</p><p><strong>Methods: </strong>The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes.</p><p><strong>Results: </strong>Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%).</p><p><strong>Conclusion: </strong>SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.</p>","PeriodicalId":16917,"journal":{"name":"Journal of radiosurgery and SBRT","volume":"9 3","pages":"215-226"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136686/pdf/","citationCount":"0","resultStr":"{\"title\":\"Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.\",\"authors\":\"Raj Singh, Robert Sierra, Casey Leimbach, Sidharth Iyer, Eric J Lehrer, Haley Perlow, Rituraj Upadhyay, Sung Jun Ma, Austin Sim, Emile Gogineni, Sujith Baliga, Daniel M Trifiletti, Joshua D Palmer, David J Konieczkowski, Jeremy Brownstein, Nicholas G Zaorzky\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers.</p><p><strong>Methods: </strong>The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes.</p><p><strong>Results: </strong>Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%).</p><p><strong>Conclusion: </strong>SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.</p>\",\"PeriodicalId\":16917,\"journal\":{\"name\":\"Journal of radiosurgery and SBRT\",\"volume\":\"9 3\",\"pages\":\"215-226\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136686/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of radiosurgery and SBRT\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiosurgery and SBRT","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.
Background: Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers.
Methods: The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes.
Results: Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%).
Conclusion: SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
